New study investigates diarrhea side effect in lung disease drug
NCT ID NCT06714812
First seen Jan 04, 2026 · Last updated May 13, 2026 · Updated 13 times
Summary
This observational study tracks 100 Caucasian patients with idiopathic pulmonary fibrosis (IPF) who are taking the drug nintedanib. The goal is to understand which patients are more likely to develop diarrhea as a side effect and how adjusting the dose can help manage it. The study does not test a new treatment but aims to improve how current therapy is managed.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for IPF are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
IRCCS Azienda Ospedaliera-Universitaria di Bologna
Bologna, Bologna, 40138, Italy
Conditions
Explore the condition pages connected to this study.